Intravenous (IV) Iron Market
完整報告名稱與涵蓋範圍
Intravenous (IV) Iron Market Research Report by Product Type (Ferric Carboxymaltose, Ferumoxytol, Iron Sucrose, Iron Isomaltoside, Ferric Gluconate, Iron Dextran, Others), by Application (Anaemia in Chronic Kidney Disease (CKD), Anaemia in Oncology, Iron Deficiency in Heart Failure, Iron Deficiency Anaemia (IDA) in Non-Dialysis Patients, Others), by Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), by End User(Hospitals and Clinics, Specialized Infusion Centres, Others), by Region (North America, Europe, Asia-Pacific, Rest of the World) Forecast till 2035
報告摘要
The Global Intravenous (IV) Iron Market is projected to reach USD 9,586.84 million by 2035, expanding at a CAGR of 9.27% during 2025–2035. The market growth is being driven by the rising prevalence of iron deficiency Anaemia and increasing demand for rapid and effective iron replacement therapies.
Clinical Superiority of IV Iron in Inflammation-Related Disorders
Chronic inflammatory diseases like chronic kidney disease, cancer, and inflammatory bowel disease lead to an increased demand for intravenous (IV) iron therapies. Oral iron may not work well during inflammation as the body's capacity to absorb iron through this route is limited. IV iron, therefore, is considered a more certain and quicker way of addressing Anaemia in these cases.
Segment Insights Overview
By Product Type
• Ferric Carboxymaltose – Widely preferred for rapid high-dose iron replacement.
• Ferumoxytol – Gaining demand due to quick administration benefits.
• Iron Sucrose – Commonly used in chronic kidney disease treatment.
• Iron Isomaltoside – Offers flexible dosing with improved patient tolerance.
• Ferric Gluconate – Preferred for controlled and gradual iron supplementation.
• Iron Dextran – Suitable for large-dose intravenous iron administration.
• Others – Emerging formulations supporting specialized therapeutic requirements.
By Application
• Anaemia in Chronic Kidney Disease (CKD) – Largest demand driven by dialysis-related Anaemia cases.
• Anaemia in Oncology – Increasing use during cancer-related Anaemia management.
• Iron Deficiency in Heart Failure – Supporting improved cardiovascular patient health outcomes.
• Iron Deficiency Anaemia (IDA) in Non-Dialysis Patients – Rising adoption among outpatient treatment populations.
• Others – Expanding applications across diverse chronic medical conditions.
By Distribution Channel
• Retail Pharmacy – Ensures convenient patient access to prescribed therapies.
• Hospital Pharmacy – Dominates distribution through inpatient treatment requirements.
• Online Pharmacy – Growing rapidly with digital healthcare adoption trends.
By End User
• Hospitals and Clinics – Primary centres for intravenous iron administration procedures.
• Specialized Infusion Centres – Increasing preference for dedicated infusion-based treatment services.
• Others – Includes ambulatory care and alternative healthcare facilities.
North America is at the forefront of the Global Intravenous (IV) Iron Market because of its sophisticated healthcare systems and the wide use of IV iron therapies in chronic disease management. On the other hand, Europe, Asia Pacific, South America, and the Middle East & Africa are experiencing increased consumption due to factors like a higher rate of Anaemia and iron deficiency disorders.
Strategic Market Expansion
In March 2025, Shield Therapeutics partnered with Kye Pharmaceuticals to introduce ACCRUFeR in Canada thereby expanding their international reach. This was an important event because ACCRUFeR is the only prescription-only oral iron therapy that is licensed in Canada.
Strategic Edge Through Patient Blood Management Programs
As public healthcare systems enhance their capabilities by implementing patient blood management (PBM) programs, the Global Intravenous (IV) Iron Market is benefiting strategically. IV iron treatments can lower the need for blood transfusions as they work well to alleviate Anaemia even before surgeries and in chronic disease scenarios which makes them both cost effective and safer for the patients.
Key Report Attributes
• Market Size 2035: USD 9,586.84 Million
• CAGR (2025-2035): 9.27%
• Base Year: 2024
• Market Forecast Period: 2025-2035
Industry Segmentations Growth
• By Product Type: Ferric Carboxymaltose - 4,124.87, Ferumoxytol - 1,340.99.
• By Application: Anaemia in Chronic Kidney Disease (CKD) - 3,586.84, Anaemia in Oncology - 2,473.47.
• By Distribution Channel: Retail Pharmacy - 2,664.00, Hospital Pharmacy - 5,253.75.
• By End User: Hospitals and Clinics - 5,649.67, Specialized Infusion Centres - 2,845.49.
授權報價
| Single User Price | $4,950 USD |
| Multi User Licence (up to 10 users) | $5,950 USD |
| Enterprisewide Price (Global Site License) | $7,250 USD |
目錄 Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ......... 21
2 MARKET INTRODUCTION ..... 23
2.1 DEFINITION ....... 23
2.2 SCOPE OF THE STUDY ............... 23
2.3 RESEARCH OBJECTIVE ........ 24
2.4 MARKET STRUCTURE ..... 25
3 RESEARCH METHODOLOGY ........... 26
3.1 OVERVIEW ........ 26
3.2 DATA FLOW ......... 27
3.2.1 DATA MINING PROCESS .... 28
3.3 PURCHASED DATABASE: ..... 29
3.4 SECONDARY SOURCES: ....... 30
3.4.1 SECONDARY RESEARCH DATA FLOW: ........ 31
3.5 PRIMARY RESEARCH: ......... 32
3.5.1 PRIMARY RESEARCH DATA FLOW: ............ 33
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ........ 34
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ......... 34
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: .............. 35
3.6.1 REVENUE ANALYSIS APPROACH .... 35
3.7 DATA FORECASTING ............ 36
3.7.1 DATA FORECASTING TECHNIQUE ............... 36
3.8 DATA MODELING ............... 37
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ....... 37
3.8.2 DATA MODELING: .............. 38
3.9 TEAMS AND ANALYST CONTRIBUTION ............. 39
4 MARKET DYNAMICS ............. 41
4.1 INTRODUCTION ...... 41
4.2 MARKET TRENDS AND GROWTH AFFECTING FACTORS ........ 42
4.3 DRIVERS .............. 42
4.3.1 CLINICAL SUPERIORITY IN INFLAMMATION-DRIVEN IRON DEFICIENCY RISING NEED FOR CONTINUOUS
SURVEILLANCE OF SUBMERGED OCEAN AREAS ........... 42
4.3.2 HOSPITAL EFFICIENCY AND RESOURCE OPTIMIZATION ...... 43
4.3.3 GUIDELINE-DRIVEN, PROTOCOLIZED DEMAND ........ 43
4.4 RESTRAINTS ......... 44
4.4.1 HIGH TREATMENT AND ADMINISTRATION COSTS .............. 44
4.4.2 SAFETY MONITORING AND INFRASTRUCTURE REQUIREMENTS ....... 45
4.4.3 UNDERDIAGNOSIS AND INCONSISTENT SCREENING PRACTICES ..... 45
4.5 OPPORTUNITY ....... 47
4.5.1 EXPANSION OF IV IRON USE IN OUTPATIENT AND DAY-CARE SETTINGS ..... 47
4.5.2 RISING FOCUS ON BLOOD MANAGEMENT AND TRANSFUSION REDUCTION ............. 47
4.5.3 UNTAPPED DEMAND IN EMERGING AND UNDERSERVED MARKETS ............. 47
5 MARKET FACTOR ANALYSIS ........... 49
5.1 REGULATORY ENVIRONMENT & COMPLIANCE .... 49
5.2 MARKET TRENDS & INNOVATION ....... 53
5.3 PATIENT DEMOGRAPHICS & DISEASE BURDENS ........... 55
5.3.1 ANEMIA IN CHRONIC KIDNEY DISEASE (CKD) ......... 55
5.3.2 ANEMIA IN ONCOLOGY ...... 55
5.3.3 IRON DEFICIENCY IN HEART FAILURE ......... 55
5.3.4 IRON DEFICIENCY ANEMIA (IDA) IN NON-DIALYSIS PATIENTS ......... 56
5.4 PRICING ANALYSIS & REIMBURSEMENT DYNAMICS ...... 56
5.4.1 PRICING ANALYSIS ............ 56
5.4.1.1 NORTH AMERICA ....... 56
5.4.1.1.1 NORTH AMERICA PRICING ANALYSIS, BY PRODUCT .... 56
5.4.1.2 EUROPE ....... 56
5.4.1.2.1 EUROPE PRICING ANALYSIS, BY PRODUCT ............... 56
5.4.1.3 APAC .......... 57
5.4.1.3.1 APAC PRICING ANALYSIS, BY PRODUCT ..... 57
5.4.1.4 REST OF THE WORLD .............. 57
5.4.1.4.1 REST OF THE WORLD PRICING ANALYSIS, BY PRODUCT ............ 57
5.4.2 REIMBURSEMENT DYNAMICS ........ 57
5.5 MARKET ENTRY & EXIT BARRIERS ........ 58
5.5.1 BARRIERS TO ENTRY ......... 58
5.5.2 BARRIERS TO EXIT ............. 59
5.6 PARTNERSHIPS & COLLABORATIONS .... 60
5.7 PESTLE ANALYSIS ............ 61
5.7.1 POLITICAL FACTORS ......... 61
5.7.2 ECONOMIC FACTORS ........ 61
5.7.3 SOCIAL FACTORS .............. 61
5.7.4 TECHNOLOGICAL FACTORS ........... 62
5.7.5 LEGAL FACTORS ............... 62
5.7.6 ENVIRONMENTAL FACTORS .......... 62
5.8 PORTER’S FIVE FORCES MODEL ......... 63
5.8.1 BARGAINING POWER OF SUPPLIERS .......... 63
5.8.2 BARGAINING POWER OF BUYERS ............... 64
5.8.3 THREAT OF NEW ENTRANTS .......... 64
5.8.4 THREAT OF SUBSTITUTES ............. 64
5.8.5 INTENSITY OF RIVALRY ..... 65
5.9 CASE STUDY ANALYSIS ...... 65
5.10 INVESTMENT & FUNDING SCENARIOS ............. 66
5.11 POST-MARKET SURVEILLANCE & SAFETY DATA .............. 68
5.12 PRODUCT PIPELINE ANALYSIS ..... 69
5.12.1 PRODUCT PIPELINE ANALYSIS ....... 69
6 GLOBAL INTRAVENOUS (IV) IRON MARKET-BY PRODUCT TYPE ........... 71
6.1 INTRODUCTION ...... 71
6.2 FERRIC CARBOXYMALTOSE ............... 73
6.3 FERUMOXYTOL ...... 73
6.4 IRON SUCROSE ...... 73
6.5 IRON ISOMALTOSIDE........... 73
6.6 FERRIC GLUCONATE ............ 74
6.7 IRON DEXTRAN ...... 74
6.8 OTHERS ............... 74
7 GLOBAL INTRAVENOUS (IV) IRON MARKET-BY APPLICATION ............... 75
7.1 INTRODUCTION ...... 75
7.2 ANEMIA IN CHRONIC KIDNEY DISEASE (CKD) ............ 77
7.3 ANEMIA IN ONCOLOGY ....... 77
7.4 IRON DEFICIENCY IN HEART FAILURE ............... 77
7.5 IRON DEFICIENCY ANEMIA (IDA) IN NON-DIALYSIS PATIENTS ..... 77
7.6 OTHERS ............... 78
8 GLOBAL INTRAVENOUS (IV) IRON MARKET-BY DISTRIBUTION CHANNEL ....... 79
8.1 INTRODUCTION ...... 79
8.2 RETAIL PHARMACY ....... 80
8.3 HOSPITAL PHARMACY .............. 80
8.4 ONLINE PHARMACY ...... 81
9 GLOBAL INTRAVENOUS (IV) IRON MARKET-BY END USER ........ 82
9.1 INTRODUCTION ...... 82
9.2 HOSPITAL AND CLINICS ............ 83
9.3 SPECIALISED INFUSION CENTERS .......... 83
9.4 OTHERS ............ 84
10 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY REGION ............ 85
10.1 OVERVIEW ........ 85
10.1.1 GLOBAL INTRAVENOUS (IV) IRON MARKE, BY REGION, 2023 VS 2032 (USD MILLION)........... 85
10.1.2 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY REGION, 2019–2035 (USD MILLION) ............ 86
10.2 NORTH AMERICA ............... 86
10.2.1 US ............ 90
10.2.2 CANADA ............... 92
10.3 EUROPE .............. 94
10.3.1 GERMANY ............. 97
10.3.2 FRANCE .... 99
10.3.3 UK ............ 101
10.3.4 SPAIN ....... 103
10.3.5 ITALY ........ 105
10.3.6 REST OF EUROPE ............... 107
10.4 ASIA-PACIFIC ....... 109
10.4.1 CHINA ....... 113
10.4.2 INDIA ........ 115
10.4.3 JAPAN ...... 117
10.4.4 SOUTH KOREA ....... 119
10.4.5 AUSTRALIA ........... 121
10.4.6 NEW ZEALAND ...... 123
10.4.7 INDONESIA ........... 125
10.4.8 REST OF ASIA-PACIFIC ...... 127
10.5 SOUTH AMERICA ........... 129
10.5.1 BRAZIL ...... 133
10.5.2 MEXICO .... 135
10.5.3 ARGENTINA .......... 137
10.5.4 REST OF SOUTH AMERICA ............. 139
10.6 MIDDLE EAST AND AFRICA ........ 141
10.6.1 GCC COUNTRIES ............... 145
10.6.2 SOUTH AFRICA ...... 147
10.6.3 REST OF MIDDLE EAST & AFRICA ............... 149
11 COMPETITIVE LANDSCAPE ............. 152
11.1 INTRODUCTION ...... 152
11.2 COMPANY MARKET SHARE ANALYSIS, 2024 ............... 152
11.3 COMPETITOR DASHBOARD .... 153
11.4 PUBLIC PLAYERS STOCK SUMMARY ...... 154
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL ...... 154
11.6 COMPETITOR'S PRODUCT INFORMATION/ PRODUCT BENCHMARKING ANALYSIS ......... 155
11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES............... 155
11.7.1 NEW PRODUCT LAUNCH/ DEVELOPMENT ......... 155
11.7.2 PARTNERSHIP/COLLABORATION, INVESTMENT, EXPANSION, AND OTHERS ..... 156
12 COMPANY PROFILES ........... 158
12.1 ABBVIE INC. ...... 158
12.1.1 COMPANY OVERVIEW ........ 158
12.1.2 FINANCIAL OVERVIEW ....... 159
12.1.3 PRODUCTS OFFERED ......... 160
12.1.4 KEY DEVELOPMENTS ........ 160
12.1.5 SWOT ANALYSIS ............... 161
12.1.6 KEY STRATEGIES ............... 161
12.2 AZURITY PHARMACEUTICALS .... 162
12.2.1 COMPANY OVERVIEW ........ 162
12.2.2 FINANCIAL OVERVIEW ....... 163
12.2.3 PRODUCTS OFFERED ......... 163
12.2.4 KEY DEVELOPMENTS ........ 164
12.2.5 SWOT ANALYSIS ............... 164
12.2.6 KEY STRATEGIES ............... 165
12.3 DAIICHI SANKYO COMPANY, LTD...... 166
12.3.1 COMPANY OVERVIEW ........ 166
12.3.2 FINANCIAL OVERVIEW ....... 167
12.3.3 PRODUCTS OFFERED ......... 168
12.3.4 KEY DEVELOPMENTS ........ 168
12.3.5 SWOT ANALYSIS ............... 169
12.3.6 KEY STRATEGIES ............... 169
12.4 SANOFI ............... 170
12.4.1 COMPANY OVERVIEW ........ 170
12.4.2 FINANCIAL OVERVIEW ....... 171
12.4.3 PRODUCTS OFFERED ......... 172
12.4.4 KEY DEVELOPMENTS ........ 172
12.4.5 SWOT ANALYSIS ............... 173
12.4.6 KEY STRATEGIES ............... 173
12.5 VIFOR PHARMA (CSL) ........ 174
12.5.1 COMPANY OVERVIEW ........ 174
12.5.2 FINANCIAL OVERVIEW ....... 175
12.5.3 PRODUCTS OFFERED ......... 176
12.5.4 KEY DEVELOPMENTS ........ 177
12.5.5 SWOT ANALYSIS ............... 178
12.5.6 KEY STRATEGIES ............... 178
12.6 PHARMACOSMOS A/S. .............. 179
12.6.1 COMPANY OVERVIEW ........ 179
12.6.2 FINANCIAL OVERVIEW ....... 180
12.6.3 PRODUCTS OFFERED ......... 180
12.6.4 KEY DEVELOPMENTS ........ 180
12.6.5 SWOT ANALYSIS ............... 181
12.6.6 KEY STRATEGIES ............... 181
12.7 ZYDUS GROUP ...... 182
12.7.1 COMPANY OVERVIEW ........ 182
12.7.2 FINANCIAL OVERVIEW ....... 183
12.7.3 PRODUCTS OFFERED ......... 183
12.7.4 KEY DEVELOPMENTS ........ 184
12.7.5 SWOT ANALYSIS ............... 184
12.7.6 KEY STRATEGIES ............... 185
12.8 ROCKWELL MEDICAL, INC. ............... 186
12.8.1 COMPANY OVERVIEW ........ 186
12.8.2 FINANCIAL OVERVIEW ....... 187
12.8.3 PRODUCTS OFFERED ......... 187
12.8.4 KEY DEVELOPMENTS ........ 188
12.8.5 SWOT ANALYSIS ............... 188
12.8.6 KEY STRATEGIES ............... 189
12.9 SHIELD THERAPEUTICS ....... 190
12.9.1 COMPANY OVERVIEW ........ 190
12.9.2 FINANCIAL OVERVIEW ....... 191
12.9.3 PRODUCTS OFFERED ......... 191
12.9.4 KEY DEVELOPMENTS ........ 192
12.9.5 SWOT ANALYSIS ............... 192
12.9.6 KEY STRATEGIES ............... 192
12.10 AMERICAN REGENT, INC ..... 193
12.10.1 COMPANY OVERVIEW ........ 193
12.10.2 FINANCIAL OVERVIEW ....... 194
12.10.3 PRODUCTS OFFERED ......... 194
12.10.4 KEY DEVELOPMENTS ........ 194
12.10.5 SWOT ANALYSIS ............... 195
12.10.6 KEY STRATEGIES ............... 195
12.11 DATA CITATIONS ............... 197
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 39
TABLE 2 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 72
TABLE 3 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 76
TABLE 4 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 80
TABLE 5 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 83
TABLE 6 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY REGION, 2019–2032 (USD MILLION) 86
TABLE 7 NORTH AMERICA: INTRAVENOUS (IV) IRON MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 87
TABLE 8 NORTH AMERICA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 88
TABLE 9 NORTH AMERICA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 88
TABLE 10 NORTH AMERICA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 89
TABLE 11 NORTH AMERICA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 89
TABLE 12 US INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 90
TABLE 13 US INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 90
TABLE 14 US INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 91
TABLE 15 US INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 91
TABLE 16 CANADA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 92
TABLE 17 CANADA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 92
TABLE 18 CANADA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 93
TABLE 19 CANADA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 93
TABLE 20 EUROPE: INTRAVENOUS (IV) IRON (UUV) MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 95
TABLE 21 EUROPE INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 95
TABLE 22 EUROPE INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 96
TABLE 23 EUROPE INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 96
TABLE 24 EUROPE INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 96
TABLE 25 GERMANY INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 97
TABLE 26 GERMANY INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 97
TABLE 27 GERMANY INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 98
TABLE 28 GERMANY INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 98
TABLE 29 FRANCE INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 99
TABLE 30 FRANCE INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 99
TABLE 31 FRANCE INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 100
TABLE 32 FRANCE INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 100
TABLE 33 UK INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 101
TABLE 34 UK INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 101
TABLE 35 UK INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 102
TABLE 36 UK INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 102
TABLE 37 SPAIN INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 103
TABLE 38 SPAIN INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 103
TABLE 39 SPAIN INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 104
TABLE 40 SPAIN INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 104
TABLE 41 ITALY INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 105
TABLE 42 ITALY INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 105
TABLE 43 ITALY INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 106
TABLE 44 ITALY INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 106
TABLE 45 REST OF EUROPE INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 107
TABLE 46 REST OF EUROPE INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 107
TABLE 47 REST OF EUROPE INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 108
TABLE 48 REST OF EUROPE INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 108
TABLE 49 ASIA-PACIFIC: INTRAVENOUS (IV) IRON MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 110
TABLE 50 ASIA-PACIFIC INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 111
TABLE 51 ASIA-PACIFC INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 111
TABLE 52 ASIA-PACIFIC INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 112
TABLE 53 ASIA-PACIFIC INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 112
TABLE 54 CHINA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 113
TABLE 55 CHINA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 113
TABLE 56 CHINA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 114
TABLE 57 CHINA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 114
TABLE 58 INDIA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 115
TABLE 59 INDIA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 115
TABLE 60 INDIA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 116
TABLE 61 INDIA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 116
TABLE 62 JAPAN INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 117
TABLE 63 JAPAN INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 117
TABLE 64 JAPAN INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 118
TABLE 65 JAPAN INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 118
TABLE 66 SOUTH KOREA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 119
TABLE 67 SOUTH KOREA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 119
TABLE 68 SOUTH KOREA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 120
TABLE 69 SOUTH KOREA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 120
TABLE 70 AUSTRALIA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 121
TABLE 71 AUSTRALIA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 121
TABLE 72 AUSTRALIA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 122
TABLE 73 AUSTRALIA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 122
TABLE 74 NEW ZEALAND INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 123
TABLE 75 NEW ZEALAND INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 123
TABLE 76 NEW ZEALAND INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 124
TABLE 77 NEW ZEALAND INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 124
TABLE 78 INDONESIA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 125
TABLE 79 INDONESIA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 125
TABLE 80 INDONESIA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 126
TABLE 81 INDONESIA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 126
TABLE 82 REST OF ASIA-PACIFIC INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 127
TABLE 83 REST OF ASIA-PACIFIC INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 127
TABLE 84 REST OF ASIA-PACIFIC INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 128
TABLE 85 REST OF ASIA-PACIFIC INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 128
TABLE 86 SOUTH AMERICA: INTRAVENONUS (IV) IRON MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 130
TABLE 87 SOUTH AMERICA: INTRAVENONUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 131
TABLE 88 SOUTH AMERICA: INTRAVENONUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 131
TABLE 89 SOUTH AMERICA: INTRAVENONUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 132
TABLE 90 SOUTH AMERICA: INTRAVENONUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 132
TABLE 91 BRAZI INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 133
TABLE 92 BRAZIL INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 133
TABLE 93 BRAZIL INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 134
TABLE 94 BRAZIL INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 134
TABLE 95 MEXICO INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 135
TABLE 96 MEXICO INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 135
TABLE 97 MEXICO INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 136
TABLE 98 MEXICO INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 136
TABLE 99 ARGENTINA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 137
TABLE 100 ARGENTINA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 137
TABLE 101 ARGENTINA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 138
TABLE 102 ARGENTINA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 138
TABLE 103 REST OF SOUTH AMERICA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 139
TABLE 104 REST OF SOUTH AMERICA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 139
TABLE 105 REST OF SOUTH AMERICA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 140
TABLE 106 REST OF SOUTH AMERICA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 140
TABLE 107 MIDDLE EAST & AFRICA: INTRAVENOUS (IV) IRON, BY COUNTRY, 2019-2035 (USD MILLION) 142
TABLE 108 MIDDLE EAST & AFRICA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 143
TABLE 109 MIDDLE EAST & AFRICA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 143
TABLE 110 MIDDLE EAST & AFRICA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 144
TABLE 111 MIDDLE EAST & AFRICA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 144
TABLE 112 GCC COUNTRIES INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 145
TABLE 113 GCC COUNTRIES INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 145
TABLE 114 GCC COUNTRIES INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 146
TABLE 115 GCC COUNTRIES INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 146
TABLE 116 SOUTH AFRICA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 147
TABLE 117 SOUTH AFRICA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 147
TABLE 118 SOUTH AFRICA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 148
TABLE 119 SOUTH AFRICA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION) 148
TABLE 120 REST OF MIDDLE EAST & AFRICA INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 149
TABLE 121 REST OF MIDDLE EAST & AFRICA INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
149
TABLE 122 REST OF MIDDLE EAST & AFRICA INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 150
TABLE 123 REST OF MIDDLE EAST & AFRICA INTRAVENOUS (IV) IRON MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 124 PUBLIC PLAYERS STOCK SUMMARY
TABLE 125 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 126 COMPETITOR'S PRODUCT INFORMATION/ PRODUCT BENCHMARKING ANALYSIS
TABLE 127 NEW PRODUCT LAUNCH
TABLE 128 PARTNERSHIP/COLLABORATION, INVESTMENT, EXPANSION, AND OTHERS
TABLE 129 ABBVIE INC.: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED
TABLE 130 ABBVIE INC.: KEY DEVELOPMENTS
TABLE 131 AZURITY PHARMACEUTICALS: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED
TABLE 132 AZURITY PHARMACEUTICALS: KEY DEVELOPMENTS
TABLE 133 DAIICHI SANKYO COMPANY, LTD.: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED
TABLE 134 DAIICHI SANKYO COMPANY, LTD.: KEY DEVELOPMENTS
TABLE 135 SANOFI: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED
TABLE 136 SANOFI: KEY DEVELOPMENTS
TABLE 137 VIFOR PHARMA (CSL): PRODUCTS/ SOLUTIONS/ SERVICES OFFERED
TABLE 138 VIFOR PHARMA (CSL): KEY DEVELOPMENTS
TABLE 139 PHARMACOSMOS A/S.: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED
TABLE 140 PHARMACOSMOS A/S.: KEY DEVELOPMENTS
TABLE 141 ZYDUS GROUP.: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED
TABLE 142 ZYDUS GROUP.: KEY DEVELOPMENTS
TABLE 143 ROCKWELL MEDICAL, INC.: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED
TABLE 144 ROCKWELL MEDICAL, INC..: KEY DEVELOPMENTS
TABLE 145 SHIELD THERAPEUTICS: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED
TABLE 146 SHIELD THERAPEUTICS. KG: KEY DEVELOPMENTS
TABLE 147 AMERICAN REGENT, INC: PRODUCTS/ SOLUTIONS/ SERVICES OFFERED
LIST OF FIGURES
FIGURE 1 GLOBAL INTRAVENOUS (IV) IRON MARKET: STRUCTURE
FIGURE 2 GLOBAL INTRAVENOUS (IV) IRON MARKET: MARKET GROWTH FACTOR ANALYSIS (2019-2035)
FIGURE 3 DRIVER IMPACT ANALYSIS (2019-2035)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2019-2035)
FIGURE 5 OPPORTUNITY IMPACT FORECAST
FIGURE 6 PORTER’S FIVE FORCES MODEL: GLOBAL INTRAVENOUS (IV) IRON MARKET
FIGURE 7 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2024 & 2035 (USD MILLION)
FIGURE 8 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY PRODUCT TYPE, 2024 (% SHARE)
FIGURE 9 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2024 & 2035 (USD MILLION)
FIGURE 10 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY APPLICATION, 2024 (% SHARE)
FIGURE 11 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2024 & 2035 (USD MILLION)
FIGURE 12 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
FIGURE 13 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY END USER, 2024 & 2035 (USD MILLION)
FIGURE 14 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY END USER, 2024 (% SHARE)
FIGURE 15 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY REGION, 2024 (% SHARE)
FIGURE 16 GLOBAL INTRAVENOUS (IV) IRON MARKET, BY REGION, 2023 VS 2032 (USD MILLION)
FIGURE 17 NORTH AMERICA MARKET ANALYSIS: INTRAVENOUS (IV) IRON MARKET, 2019-2035 (USD MILLION)
FIGURE 18 NORTH AMERICA: INTRAVENOUS (IV) IRON MARKET SHARE, BY COUNTRY, 2024 (% SHARE)
FIGURE 19 EUROPE MARKET ANALYSIS: INTRAVENOUS (IV) IRON MARKET, 2019-2035 (USD MILLION)
FIGURE 20 EUROPE: INTRAVENOUS (IV) IRON MARKET SHARE, BY COUNTRY, 2024 (% SHARE)
FIGURE 21 ASIA-PACIFIC MARKET ANALYSIS: INTRAVENOUS (IV) IRON MARKET, 2019-2035 (USD MILLION)
FIGURE 22 ASIA-PACIFIC: INTRAVENOUS (IV) IRON MARKET SHARE, BY COUNTRY, 2024 (% SHARE)
FIGURE 23 SOUTH AMERICA MARKET ANALYSIS: INTRAVENONUS (IV) IRON MARKET, 2019-2035 (USD MILLION)
FIGURE 24 SOUTH AMERICA: INTRAVENONUS (IV) IRON MARKET SHARE, BY COUNTRY, 2024 (% SHARE)
FIGURE 25 MIDDLE EAST AND AFRICA MARKET ANALYSIS: INTRAVENOUS (IV) IRON MARKET, 2019-2035 (USD MILLION)
FIGURE 26 MIDDLE EAST & AFRICA: INTRAVENOUS (IV) IRON MARKET SHARE, BY COUNTRY, 2024 (% SHARE)
FIGURE 27 GLOBAL INTRAVENOUS (IV) IRON PLAYERS: COMPETITIVE ANALYSIS, 2024 (USD BILLION) (% SHARE)
FIGURE 28 COMPETITOR DASHBOARD: GLOBAL INTRAVENOUS (IV) IRON MARKET
FIGURE 44 SHIELD THERAPEUTICS: SWOT ANALYSIS
FIGURE 45 AMERICAN REGENT, INC: SWOT ANALYSIS
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們